news
$5 billion bispecific antibody pharma collaboration
As part of a $5 billion collaboration, Akeso Inc. will out-license its PD-1-based bispecific antibody ivonescimab to Summit Therapeutics.
List view / Grid view
Cancer
news
Vaccines Europe launches first pipeline review
In its first pipeline review, Vaccines Europe has set out four key actions to ensure adults are protected from vaccine-preventable diseases.
news
mRNA non-vaccine therapeutics to generate $2 billion by 2028
Driven by the approval of pipeline agents, mRNA non-vaccine therapeutics are set to reach $2 billion in sales by 2028, says GlobalData.
news
AstraZeneca to acquire Neogene for $320 million
AstraZeneca is set to acquire Neogene Therapeutics to advance T-cell receptor therapies for hard-to-treat cancers like solid tumours.
news
Live from CPhI: ‘Gut microbiome therapy to be approved in the next two years’
The promise of microbiome-based therapeutics is rapidly progressing towards real world applications as treatment of recurrent Clostridium difficile using faecal microbiota transplant edges towards a BLA.
news
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
Janus kinase inhibitors used for chronic inflammatory conditions are only safe for certain patients, advises the EMA’s safety committee.
news
Outsourcing APIs put EU patients at risk
Teva warns APIs could disappear from European factories in five to 10 years if the industry does not see outsourcing essential medicine manufacture as risky.
news
First patient receives novel, potentially cancer-stopping pill
City of Hope has developed AOH1996, a promising cancer medicine, for people with reoccurring solid tumours.
news
HPAPI contract manufacturing to value $14.6 billion by 2030
Rising demand for cancer drugs, combined with high in-house manufacturing costs is driving growth in the high-potency API outsourcing market.
news
Novel cancer therapeutic synthesised by Stanford researchers
The natural compound tigilanol tiglate was produced in a lab for the first time by scientists at Stanford University, suggesting it could provide treatment for a variety of cancers.
news
OSD contract manufacturing market valued at $54.7 billion by 2030
Outsourcing the production of oral solids is estimated to be the primary influencer for the contract manufacturing market in the next decade, using lessons learnt from the COVID-19 pandemic.
news
Diagnostic approval facilitates more cancer patients treatment
The US FDA has approved Roche’s companion diagnostic test which identifies low HER2 expression in metastatic breast cancer, increasing pool of patients eligible for treatment with antibody drug conjugate Enhertu.
news
Quantifying proteins en masse using coulometric mass spectrometry
Coulometric mass spectrometry (CMS) fully quantities proteins without using traditional lab sample testing standards, promising faster vaccine and drug advancement.
news
GM herpes virus fights advanced cancers
A Phase I trial showed early potential in using a genetically engineered herpes virus to combat advanced cancers that exhibited no response to immunotherapies.
article
Actualising the power of antibody-drug conjugates as cancer therapeutics
Antibody-drug conjugates (ADCs) are designed to be highly-targeted therapies with the potential to maximise the potency of a treatment while reducing unwanted side effects on healthy tissues. Some 20 years after the first ADC product approval, Dominik Schumacher and Jonas Helma-Smets of Tubulis GmbH discuss how improved and optimised technologies…
